Could a tailored diet make a MASH drug work better?

NCT ID NCT07680478

Not yet recruiting Disease control Sponsor: City University of New York Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This study tests whether adding a Mediterranean-style meal delivery program to resmetirom therapy improves liver health more than resmetirom alone. It involves 120 adults with non-cirrhotic MASH who are starting resmetirom. Participants either receive the drug plus 10 medically tailored meals per week or the drug alone, and liver fat and stiffness are measured after one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Resmetirom
What this could lead to: If it works, this could show that combining a liver-targeting drug with a tailored diet leads to better liver health than the drug alone.
What could go wrong: This is a mid-stage trial with only 120 participants, so results may not apply to everyone. The diet program is limited to New York City, and the drug may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatohepatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)

Contacts and locations

Locations

CUNY Graduate School of Public Health and Health Policy

New York, New York, 10027, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.